answer text |
<p>We have referred a number of high cost, low volume technologies to the National
Institute for Health and Care Excellence (NICE) for evaluation under its highly specialised
technologies work programme. We will continue to do so for technologies that meet
the specified criteria and where a NICE evaluation would add value. Only today, Ministers
referred the drug Translarna (ataluren) for Duchenne muscular dystrophy, to NICE’s
work programme.</p><p> </p><p> </p><p> </p><p>Further information about the process
by which topics are selected for referral to NICE’s highly specialised technologies
work programme is available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/about/what-we-do/our-programmes/topic-selection"
target="_blank">www.nice.org.uk/about/what-we-do/our-programmes/topic-selection</a></p><p>
</p>
|
|